269 related articles for article (PubMed ID: 25583753)
1. Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.
Demeester S; Keymeulen B; Kaufman L; Van Dalem A; Balti EV; Van de Velde U; Goubert P; Verhaeghen K; Davidson HW; Wenzlau JM; Weets I; Pipeleers DG; Gorus FK
Diabetes Care; 2015 Apr; 38(4):644-51. PubMed ID: 25583753
[TBL] [Abstract][Full Text] [Related]
2. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
Keymeulen B; van Maurik A; Inman D; Oliveira J; McLaughlin R; Gittelman RM; Roep BO; Gillard P; Hilbrands R; Gorus F; Mathieu C; Van de Velde U; Wisniacki N; Napolitano A
Diabetologia; 2021 Feb; 64(2):313-324. PubMed ID: 33145642
[TBL] [Abstract][Full Text] [Related]
3. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Aronson R; Gottlieb PA; Christiansen JS; Donner TW; Bosi E; Bode BW; Pozzilli P;
Diabetes Care; 2014 Oct; 37(10):2746-54. PubMed ID: 25011949
[TBL] [Abstract][Full Text] [Related]
4. Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials.
De Grijse J; Asanghanwa M; Nouthe B; Albrecher N; Goubert P; Vermeulen I; Van Der Meeren S; Decochez K; Weets I; Keymeulen B; Lampasona V; Wenzlau J; Hutton JC; Pipeleers D; Gorus FK;
Diabetologia; 2010 Mar; 53(3):517-24. PubMed ID: 20091020
[TBL] [Abstract][Full Text] [Related]
5. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L
N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866
[TBL] [Abstract][Full Text] [Related]
6. Contribution of antibodies against IA-2β and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age.
Vermeulen I; Weets I; Asanghanwa M; Ruige J; Van Gaal L; Mathieu C; Keymeulen B; Lampasona V; Wenzlau JM; Hutton JC; Pipeleers DG; Gorus FK;
Diabetes Care; 2011 Aug; 34(8):1760-5. PubMed ID: 21715527
[TBL] [Abstract][Full Text] [Related]
7. Antibodies against insulin measured by electrochemiluminescence predicts insulitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status.
Lo B; Swafford AD; Shafer-Weaver KA; Jerome LF; Rakhlin L; Mathern DR; Callahan CA; Jiang P; Davison LJ; Stevens HE; Lucas CL; White J; von Borstel R; Todd JA; Lenardo MJ
J Transl Med; 2011 Nov; 9():203. PubMed ID: 22123298
[TBL] [Abstract][Full Text] [Related]
8. High-titer autoantibodies against glutamic acid decarboxylase plus autoantibodies against insulin and IA-2 predicts insulin requirement in adult diabetic patients.
Kasuga A; Maruyama T; Nakamoto S; Ozawa Y; Suzuki Y; Saruta T
J Autoimmun; 1999 Mar; 12(2):131-5. PubMed ID: 10047433
[TBL] [Abstract][Full Text] [Related]
9. Baseline plasma proinsulin response to glucose for predicting therapeutic response to otelixizumab in recent-onset type 1 diabetes.
Desouter AK; Keymeulen B; Demeester S; Van de Velde U; De Pauw P; Van Dalem A; Lapauw B; De Block C; Gillard P; Pipeleers DG; Gorus FK
Diabetes Res Clin Pract; 2023 Nov; 205():110974. PubMed ID: 37884063
[TBL] [Abstract][Full Text] [Related]
10. A simple screening method for individuals at risk of developing type 1 diabetes: measurement of islet cell autoantibodies (GADA, IA-2A, and IAA) on dried capillary blood spots collected on filter paper.
Siraj ES; Rogers DG; Gupta MK; Reddy SS
Horm Metab Res; 2012 Oct; 44(11):855-60. PubMed ID: 22893260
[TBL] [Abstract][Full Text] [Related]
11. Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?
Fouts A; Pyle L; Yu L; Miao D; Michels A; Krischer J; Sosenko J; Gottlieb P; Steck AK;
Diabetes Care; 2016 Oct; 39(10):1738-44. PubMed ID: 27456836
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies to insulin, insulinoma-associated antigen-2, and zinc transporter 8 improve the prediction of early insulin requirement in adult-onset autoimmune diabetes.
Kawasaki E; Nakamura K; Kuriya G; Satoh T; Kuwahara H; Kobayashi M; Abiru N; Yamasaki H; Eguchi K
J Clin Endocrinol Metab; 2010 Feb; 95(2):707-13. PubMed ID: 20061424
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study.
Ambery P; Donner TW; Biswas N; Donaldson J; Parkin J; Dayan CM
Diabet Med; 2014 Apr; 31(4):399-402. PubMed ID: 24236828
[TBL] [Abstract][Full Text] [Related]
14. Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and
Gorus FK; Balti EV; Messaaoui A; Demeester S; Van Dalem A; Costa O; Dorchy H; Mathieu C; Van Gaal L; Keymeulen B; Pipeleers DG; Weets I;
Diabetes Care; 2017 Aug; 40(8):1065-1072. PubMed ID: 28701370
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.
Guglielmi C; Williams SR; Del Toro R; Pozzilli P
Expert Opin Biol Ther; 2016 Jun; 16(6):841-6. PubMed ID: 27145230
[TBL] [Abstract][Full Text] [Related]
16. Short duration of breast-feeding as a risk-factor for beta-cell autoantibodies in 5-year-old children from the general population.
Holmberg H; Wahlberg J; Vaarala O; Ludvigsson J;
Br J Nutr; 2007 Jan; 97(1):111-6. PubMed ID: 17217566
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility.
Pöllänen PM; Lempainen J; Laine AP; Toppari J; Veijola R; Vähäsalo P; Ilonen J; Siljander H; Knip M
Diabetologia; 2017 Jul; 60(7):1284-1293. PubMed ID: 28364254
[TBL] [Abstract][Full Text] [Related]
18. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes.
Decochez K; Truyen I; van der Auwera B; Weets I; Vandemeulebroucke E; de Leeuw IH; Keymeulen B; Mathieu C; Rottiers R; Pipeleers DG; Gorus FK;
Diabetologia; 2005 Apr; 48(4):687-94. PubMed ID: 15756536
[TBL] [Abstract][Full Text] [Related]
19. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes In Finland Study Group.
Sabbah E; Savola K; Kulmala P; Veijola R; Vähäsalo P; Karjalainen J; Akerblom HK; Knip M
J Clin Endocrinol Metab; 1999 May; 84(5):1534-9. PubMed ID: 10323375
[TBL] [Abstract][Full Text] [Related]
20. An improved clinical model to predict stimulated C-peptide in children with recent-onset type 1 diabetes.
Buchanan K; Mehdi AM; Hughes I; Cotterill A; Le Cao KA; Thomas R; Harris M
Pediatr Diabetes; 2019 Mar; 20(2):166-171. PubMed ID: 30556344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
